Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 476 - 500 of 15139 in total

Insulin glulisine

Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. ... This recombinant hormone differs from native human insulin in that the amino acid asparagine at position ... and proteolysis among many other functions. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Insulins and Analogues for Injection, Fast-Acting ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Plecanatide

Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Approved
Investigational
Matched Iupac: … 14.13.13]dotetraconta-2,5,8,11,14,17,20,23,30,33,36-undecaen-25-yl]-C-hydroxycarbonimidoyl}butanoic acid …
Matched Description: … It should not be used in children less than six years of age, and should be avoided in patients six years …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Levetiracetam

Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918]...
Approved
Matched Description: … It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated ... [L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no ... choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and …

Tecovirimat

The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses,...
Approved
Investigational
Matched Description: … to treat monkeypox and cowpox in adults and children. ... [L40154] Tecovirimat is available as both oral and intravenous formulations.[L41835] ... The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, …

Procarbazine

An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Approved
Investigational
Matched Description: … An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …

Betamethasone phosphate

Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors. Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium and water retention. Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.
Approved
Vet approved
Matched Iupac: … 1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}phosphonic acid …
Matched Description: … L11994] Betamethasone provides greater anti-inflammatory activity than [prednisolone] with less sodium and …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Damoctocog alfa pegol

In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. Also known as, BAY94-9027,...
Approved
Investigational
Matched Description: … and gained approval. ... has been filed with the FDA in August 2017 and FDA approved in August 2018. ... In recent years, various extended half-life factor VIII and factor IX preparations have been studied …

Bivalirudin

Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in...
Approved
Investigational
Matched Iupac: … carbamoyl}propyl]carbamoyl}propyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl}butanoic acid …
Matched Description: … monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Hydroxyzine

Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine,...
Approved
Matched Description: … piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties. ... Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and ... for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. …
Matched Categories: … Miscellaneous Anxiolytics Sedatives and Hypnotics …

Trandolapril

Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...
Approved
Matched Iupac: … -[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid …
Matched Description: … ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS ... to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and ... stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and …
Matched Mixtures name: … Trandolapril and Verapamil Hydrochloride ... Trandolapril and Verapamil Hydrochloride ... Trandolapril and Verapamil Hydrochloride …
Matched Categories: … trandolapril and verapamil ... ACE Inhibitors and Calcium Channel Blockers …

Racemethionine

A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.
Approved
Experimental
Matched Iupac: … 2-amino-4-(methylsulfanyl)butanoic acid …
Matched Description: … A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers. …
Matched Mixtures name: … Swiss One Multivitamin and Mineral Caplet ... Vita Vim Multivitamins and Minerals Tab ... Super Vita Vim Multivitamins and Minerals …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Dibenzepin

Dibenzepin is approved for use in Europe.
Approved

Pramiracetam

Pramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. It was also previously approved in the United States with orphan drug designation . Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive...
Approved
Matched Description: … previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and ... Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore …
Matched Categories: … Psychostimulants, Agents Used for ADHD and Nootropics …

Nortriptyline

Nortriptyline hydrochloride, the active metabolite of amitriptyline, is a tricyclic antidepressant (TCA). It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions.
Approved
Matched Description: … and other conditions. ... [L11878] It is used in the treatment of major depression and is also used off-label for chronic pain …
Matched Categories: … Tricyclics and Other Norepinephrine-reuptake Inhibitors …

Fluvoxamine

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised...
Approved
Investigational
Matched Description: … It was launched in the US in December 1994 and in Japan in June 1999. ... Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …

Ramelteon

Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Approved
Investigational
Matched Description: … Ramelteon has not been shown to produce dependence and has shown no potential for abuse. …
Matched Categories: … Hypnotics and Sedatives …

Tigecycline

Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Approved
Matched Description: … Food and Drug Administration (FDA) on June 17, 2005. ... Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil …

Crisaborole

Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … reducing the signs and symptoms in patients 2 years old and older. ... It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a ... This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and …

Trovafloxacin

Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective...
Approved
Investigational
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid …
Matched Description: … inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and …

Sofosbuvir

Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the...
Approved
Matched Description: … count, and neuropsychiatric effects [A19635]. ... for its high replicative rate and genetic diversity [A19594]. ... achieve a SVR between 93 and 99% after 12 weeks of treatment [A7535]. …
Matched Mixtures name: … Ledipasvir and Sofosbuvir ... Sofosbuvir and Velpatasvir …
Matched Categories: … sofosbuvir and ledipasvir ... sofosbuvir and velpatasvir ... sofosbuvir, velpatasvir and voxilaprevir ... Nucleic Acids, Nucleotides, and Nucleosides …

Clobazam

Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others. . Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has...
Approved
Illicit
Matched Description: … , Frisium, Urbanyl, and others. ... children aged two years and older. ... and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …

Strontium ranelate

Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. Some reports have shown that strontium ranelate can slow down the progression of osteoarthritis of the knee. This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and,...
Approved
Withdrawn
Matched Description: … Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. ... intrinsic bone tissue quality and microarchitecture in osteoporosis by way of a number of cellular and ... presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and …
Matched Categories: … strontium ranelate and colecalciferol ... Drugs Affecting Bone Structure and Mineralization …

Remimazolam

Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid...
Approved
Investigational
Matched Description: … thus susceptible to rapid biotransformation and elimination as inactive metabolites. ... Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation ... [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and …

Bimatoprost

Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as...
Approved
Investigational
Matched Description: … Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. ... the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and ... [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis …
Matched Categories: … Antiglaucoma Preparations and Miotics …
Displaying drugs 476 - 500 of 15139 in total